万邦德医药控股集团股份有限公司2025年度业绩预告

Group 1 - The company expects a negative net profit for the fiscal year 2025, from January 1 to December 31 [2][3] - The company has communicated with the accounting firm regarding the earnings forecast, and there are no significant disagreements [3] Group 2 - The decline in profit is attributed to the ongoing impact of national drug and medical device procurement policies, leading to significant price reductions and intensified market competition [4] - The company is transitioning from generic drugs to innovative drugs, increasing R&D investment and global development efforts [5] - The company has made substantial investments in international standard facilities for innovative drug production, which has increased fixed asset depreciation without achieving scale effects [5] - The relocation of the polymer product manufacturing site has affected the production and market supply of medical devices [6]